Name
C-TPF
Alternate names
None
Primary Site
Histology
Radiation
None
Remarks
Drugs for C-TPF
Name
Alternate Names
5-Fluorouracil
5-Fluracil
Adrucil
Efudex
Fluoroplex
Fluracil
Fluril
Oracil
Ro 2-9757
WR-69596
Abbreviations
5-FU
5FU
FU
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
019893
19893
Primary Site
Breast- adjuvant setting and advanced disease
colorectal- adjuvant setting and advanced disease
GI malignancies: anal, esophageal, gastric and pancreatic
Hepatoma
Ovarian cancer
Histology
None
Remarks
Fluorinated pyrimidine; antimetabolite. FDA approved uses on basal cell carcinoma, breast cancer, colorectal cancer, gastric cancer, and pancreatic cancer.
Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.
Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.
Coding
This drug should be coded
Name
Alternate Names
LIT-976
RP-56976
Taxotere
Abbreviations
None
Category
Chemotherapy
Subcategory
Taxane
NSC Number
628503
Primary Site
Histology
None
Remarks
Coding
This drug should be coded
Name
Alternate Names
Cis-Platin
Cis-Platinum II#
Cisplatino (Spanish)
Cisplatinum
Cisplatyl
Neoplatin
Peyrone's chloride
Platinex
Platinol
Platinol-AQ
Platinol-AQ VHA Plus
Platinum
Abbreviations
CACP
CDDP
Cis-DDP
CPD
CPDC
CPDD
CPPD
DDP
Category
Chemotherapy
Subcategory
Alkylating agent
Platinum analog
NSC Number
119875
Primary Site
Histology
None
Remarks
An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.
Coding
This drug should be coded
Name
Alternate Names
C 225
C-225
C225
Erbitux
IMC-C225
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
NSC Number
714692
Primary Site
Histology
None
Remarks
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, cetuximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code cetuximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.
FDA approved colorectal 2004, head and neck 2006; orphan drug for pancreas
Anti-VEGFr chimeric monoclonal antibody.
FDA approved colorectal 2004, head and neck 2006; orphan drug for pancreas
Anti-VEGFr chimeric monoclonal antibody.
Coding
This drug should be coded